Literature DB >> 26047621

Pathology and function of conduction tissue in Fabry disease cardiomyopathy.

Andrea Frustaci1, Emanuela Morgante2, Matteo A Russo2, Fernanda Scopelliti2, Claudia Grande2, Romina Verardo2, Pasquale Franciosa2, Cristina Chimenti2.   

Abstract

BACKGROUND: Cardiac arrhythmias are common in Fabry disease (FD) and may occur in prehypertrophic cardiomyopathy suggesting an early compromise of conduction tissue (CT). Therefore, FD X-linked and CT may be variously involved in male and female patients with FD cardiomyopathy, affecting CT function. METHODS AND
RESULTS: Among 74 patients with endomyocardial biopsy diagnosis of FD cardiomyopathy, 13 (6 men; 7 women; mean age, 50.1±13.5 years; maximal wall thickness, 16.7±3.7 mm) had CT included in histological specimens and 6 also at electron microscopy. CT glycolipid infiltration was defined as focal, moderate, extensive, or massive, if involved ≤30%, ≤50%, >50%, or 100% of cells; identified as loosely arranged small myocytes positive to HCN4 immunostaining, supplied by a centrally placed thick-walled arteriole. CT involvement was correlated with age, sex, and α-Gal gene mutation. CT function was evaluated by electrophysiological study and arrhythmias at Holter registration. CT infiltration was focal/moderate in 4 women with no arrhythmias and normal electrophysiological study, extensive in 3 women with atrial or ventricular arrhythmias and short HV interval, and massive in 6 men with atrial fibrillation or ventricular arrhythmias and short HV. Short PR/AH with increased refractoriness was additionally found in 3 patients with extensive/massive CT infiltration. A male patient with the shortest HV presented infra-Hissian block during decremental atrial stimulation. There was no correlation with age, maximal wall thickness, and type of gene mutation.
CONCLUSIONS: CT infiltration in FD cardiomyopathy is constant in men and variable in women because of skewed X-chromosome inactivation; its extensive/massive involvement causes accelerated conduction with prolonged refractoriness and electric instability.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  Fabry disease; arrhythmias; cardiac; cardiomyopathies; electron; microscopy; mutation

Mesh:

Year:  2015        PMID: 26047621     DOI: 10.1161/CIRCEP.114.002569

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  10 in total

1.  Severe bradyarrhythmia linked to left atrial dysfunction in Fabry disease-A cross-sectional study.

Authors:  Lu Zhao Di; Maxime Pichette; Réginald Nadeau; Daniel G Bichet; Frédéric Poulin
Journal:  Clin Cardiol       Date:  2018-09-20       Impact factor: 2.882

2.  Transitory ventricular tachycardia associated with influenza A infection of cardiac conduction tissue.

Authors:  Andrea Frustaci; Nicola Petrosillo; Giuseppe Ippolito; Cristina Chimenti
Journal:  Infection       Date:  2016-03-26       Impact factor: 3.553

3.  Limited effects of long-term enzyme replacement therapy on the cardiac conduction system in Fabry disease.

Authors:  Tomoya Kaneda; Masahiro Takeda; Tetsuro Suematsu; Ryusuke Yamamoto; Mutsuko Takata; Toshinori Higashikata; Hidekazu Ino; Akihiko Tsujibata; Kenshi Hayashi; Noboru Fujino; Masa-Aki Kawashiri
Journal:  J Cardiol Cases       Date:  2018-02-09

4.  Massive accumulation of globotriaosylceramide in various tissues from a Fabry patient with a high antibody titer against alpha-galactosidase A after 6 years of enzyme replacement therapy.

Authors:  Kenichi Hongo; Toru Harada; Eiko Fukuro; Masahisa Kobayashi; Toya Ohashi; Yoshikatsu Eto
Journal:  Mol Genet Metab Rep       Date:  2020-07-16

5.  Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathy.

Authors:  Ravi Vijapurapu; Tarekegn Geberhiwot; Ana Jovanovic; Shanat Baig; Sabrina Nordin; Rebecca Kozor; Francisco Leyva; Dipak Kotecha; Nigel Wheeldon; Patrick Deegan; Rosemary A Rusk; James C Moon; Derralynn A Hughes; Peter Woolfson; Richard P Steeds
Journal:  Heart       Date:  2019-08-24       Impact factor: 5.994

6.  Fabry Disease with Pacemaker Implantation as the Initial Event.

Authors:  Yuji Kato; Ayako Ishikawa; Satoshi Aoki; Hiroyuki Sato; Yoshie Ojima; Saeko Kagaya; Tasuku Nagasawa
Journal:  Intern Med       Date:  2019-06-27       Impact factor: 1.271

7.  Cardiac device implantation and device usage in Fabry and hypertrophic cardiomyopathy.

Authors:  Richard P Steeds; Tarekegn Geberhiwot; Ravi Vijapurapu; William Bradlow; Francisco Leyva; James C Moon; Abbasin Zegard; Nigel Lewis; D Kotecha; Ana Jovanovic; Derralynn A Hughes; Peter Woolfson
Journal:  Orphanet J Rare Dis       Date:  2022-01-06       Impact factor: 4.123

8.  Clinical and genetic spectrum in Chinese families with Fabry disease: a single-centre case series.

Authors:  Xin Chen; Hezhi Li; Hongtao Liao; Xianzhang Zhan; Zhian Zhong; Qianhuan Zhang; Lie Liu; Yuanhong Liang; Hai Deng; Xianhong Fang; Yumei Xue; Shulin Wu; Yang Liu
Journal:  ESC Heart Fail       Date:  2021-10-26

Review 9.  Hypertrophic Cardiomyopathy and Primary Restrictive Cardiomyopathy: Similarities, Differences and Phenocopies.

Authors:  Riccardo Vio; Annalisa Angelini; Cristina Basso; Alberto Cipriani; Alessandro Zorzi; Paola Melacini; Gaetano Thiene; Alessandra Rampazzo; Domenico Corrado; Chiara Calore
Journal:  J Clin Med       Date:  2021-05-01       Impact factor: 4.241

Review 10.  Electrocardiographic Changes and Arrhythmia in Fabry Disease.

Authors:  Mehdi Namdar
Journal:  Front Cardiovasc Med       Date:  2016-03-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.